Breaking News Instant updates and real-time market news.

TXMD

TherapeuticsMD

$5.30

-0.33 (-5.86%)

14:53
07/17/17
07/17
14:53
07/17/17
14:53

Stifel sees high likelihood FDA lets TherapeuticsMD do post-marketing study

Stifel analyst Annabel Samimy said a lack of clarity is pressuring TherapeuticsMD shares after the company provided a regulatory update on the status of its New Drug Application for TX-004HR, but he thinks there is a high likelihood that the FDA will allow the company to proceed with a post-marketing safety study. Samimy, who still expects a resubmission within weeks and FDA action within two months, keeps a Buy rating and $20 price target on TherapeuticsMD.

TXMD TherapeuticsMD
$5.30

-0.33 (-5.86%)

05/23/17
STFL
05/23/17
NO CHANGE
Target $20
STFL
Buy
TherapeuticsMD scheduled to meet FDA on June 14, says Stifel
Stifel analyst Annabel Samimy says TherapeuticsMD's Type A meeting with the FDA to discuss last month's Complete Response Letter is scheduled for June 14. The analyst sees two likely scenarios from the meeting. The first has TherapeuticsMD seeking class labeling with a Phase 4 post-marketing study to eventually amend the label. And the second has the company seeking an appeal should FDA hold firm in the 12-month safety requirement to justify a differentiated label. Samimy is "convinced" that TX-004HR remains approvable and she keeps a Buy rating on the shares with a $20 price target.
06/13/17
JEFF
06/13/17
NO CHANGE
JEFF
TherapeuticsMD could use data to push post-approval study, says Jefferies
Jefferies analyst Matthew Andrews says that TherapeuticsMD could use prior data - including a finding that low-dose vaginal estrogen is safe for women with breast cancer and a finding that estrogen delivered in a patch is safe for two years - to convince an FDA panel to allow the company to address concerns raised in a complete response letter for its TX-004 drug with a post-approval study instead of a pre-approval study. Andrews keeps a $15 price target and a buy rating on the shares.
07/11/17
OPCO
07/11/17
UPGRADE
Target $10
OPCO
Outperform
TherapeuticsMD upgraded to Outperform from Perform at Oppenheimer
Oppenheimer analyst Jay Olson upgraded TherapeuticsMD to Outperform with a $10 price target.
07/11/17
OPCO
07/11/17
UPGRADE
Target $10
OPCO
Outperform
TherapeuticsMD upgraded ahead of FDA meeting update at Oppenheimer
Oppenheimer analyst Jay Olson upgraded TherapeuticsMD to Outperform from Perform with a $10 price target. The stock closed yesterday down 21c to $4.80. Details of the company's meeting with the FDA are likely to be announced around July 14 and there is a "reasonable probability" of positive news, Olson tells investors in a research note. Evidence supports a scenario where TherapeuticsMD is likely to resubmit TX-004HR by July 31 with a potential FDA approval by September 29 in the best case, the analyst adds. He assigns a 60% probability to this scenario.

TODAY'S FREE FLY STORIES

ACRS

Aclaris Therapeutics

$29.18

-0.46 (-1.55%)

04:55
07/28/17
07/28
04:55
07/28/17
04:55
Conference/Events
Aclaris Therapeutics management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Breaking General news story  »

Week of 7/28 Baker-Hughes…

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Consumer Sentiment Index to be reported at 10:00 »

Consumer Sentiment Index…

JAGX

Jaguar Animal Health

$0.66

-0.0175 (-2.58%)

04:55
07/28/17
07/28
04:55
07/28/17
04:55
Conference/Events
Jaguar Animal Health to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
GDP price index to be reported at 08:30 »

GDP price index will be…

CALM

Cal-Maine Foods

$38.05

0.55 (1.47%)

04:55
07/28/17
07/28
04:55
07/28/17
04:55
Conference/Events
Cal-Maine Foods participates in a conference call with Stephens »

Stephens hosts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Real GDP to be reported at 08:30 »

Real GDP will be reported…

BAESY

BAE Systems

$32.23

0.145 (0.45%)

, IBM

IBM

$145.07

-0.29 (-0.20%)

04:55
07/28/17
07/28
04:55
07/28/17
04:55
Conference/Events
RSA Security to hold a conference »

RSA Security Conference…

BAESY

BAE Systems

$32.23

0.145 (0.45%)

IBM

IBM

$145.07

-0.29 (-0.20%)

CTL

CenturyLink

$23.60

0.74 (3.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 08

    Aug

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Breaking General news story  »

Minneapolis Federal…

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Employment Cost Index ECI to be reported at 08:30 »

Employment Cost Index ECI…

03:35
07/28/17
07/28
03:35
07/28/17
03:35
General news
FX Action: USD-CAD steady after posting its biggest one-day gain »

FX Action: USD-CAD steady…

01:40
07/28/17
07/28
01:40
07/28/17
01:40
General news
FX Update: The Swiss franc tumbled for a four straight session »

FX Update: The Swiss…

TOO

Teekay Offshore Partners

$2.55

-0.03 (-1.16%)

20:27
07/27/17
07/27
20:27
07/27/17
20:27
Downgrade
Teekay Offshore Partners rating change at Raymond James »

Teekay Offshore…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QEP

QEP Resources

$7.93

-1.34 (-14.46%)

20:26
07/27/17
07/27
20:26
07/27/17
20:26
Downgrade
QEP Resources rating change at JPMorgan »

QEP Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 14

    Aug

RDFN

Redfin

20:26
07/27/17
07/27
20:26
07/27/17
20:26
Syndicate
Redfin 9.231M share IPO priced at $15.00 »

The deal range is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 28

    Jul

XOM

Exxon Mobil

$80.83

0.46 (0.57%)

, CVX

Chevron

$106.11

0.99 (0.94%)

20:25
07/27/17
07/27
20:25
07/27/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

XOM

Exxon Mobil

$80.83

0.46 (0.57%)

CVX

Chevron

$106.11

0.99 (0.94%)

MRK

Merck

$63.69

1.89 (3.06%)

ABBV

AbbVie

$71.73

-0.86 (-1.18%)

AAL

American Airlines

$50.00

-1.01 (-1.98%)

COL

Rockwell Collins

$109.02

-0.53 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 28

    Jul

  • 28

    Jul

  • 28

    Jul

  • 28

    Jul

  • 28

    Jul

  • 07

    Aug

  • 28

    Aug

  • 22

    Sep

TTPH

Tetraphase

$6.96

-0.92 (-11.68%)

20:22
07/27/17
07/27
20:22
07/27/17
20:22
Syndicate
Tetraphase 10M share Secondary priced at $6.50 »

Piper Jaffray, BMO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

BVN

Buenaventura

$12.45

0.1 (0.81%)

19:26
07/27/17
07/27
19:26
07/27/17
19:26
Earnings
Buenaventura reports Q2 EPS (2c), may not compare to consensus 26c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAS

Basic Energy

$28.67

0.06 (0.21%)

19:02
07/27/17
07/27
19:02
07/27/17
19:02
Hot Stocks
Breaking Hot Stocks news story on Basic Energy »

Basic Energy backs FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 14

    Aug

BAS

Basic Energy

$28.67

0.06 (0.21%)

19:01
07/27/17
07/27
19:01
07/27/17
19:01
Earnings
Basic Energy reports Q2 adjusted EPS (57c), consensus (55c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 14

    Aug

GE

General Electric

$25.79

0.2 (0.78%)

18:55
07/27/17
07/27
18:55
07/27/17
18:55
Periodicals
Breaking Periodicals news story on General Electric »

Uber CEO shortlists…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AIV

Aimco

$44.01

0.13 (0.30%)

18:53
07/27/17
07/27
18:53
07/27/17
18:53
Earnings
Aimco reports Q2 AFFO 51c vs 50c last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

NOV

National Oilwell

$33.71

0.37 (1.11%)

18:43
07/27/17
07/27
18:43
07/27/17
18:43
Earnings
National Oilwell reports Q2 adjusted EPS (14c), consensus (15c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 29

    Aug

AIG

AIG

$65.17

-0.02 (-0.03%)

, IEP

Icahn Enterprises

$53.12

-0.78 (-1.45%)

18:39
07/27/17
07/27
18:39
07/27/17
18:39
Periodicals
Senators worried over whether Icahn is pushing regulators on AIG, Reuters says »

U.S. Democratic Senators…

AIG

AIG

$65.17

-0.02 (-0.03%)

IEP

Icahn Enterprises

$53.12

-0.78 (-1.45%)

PRU

Prudential

$112.74

0.55 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 03

    Aug

  • 27

    Sep

HTBK

Heritage Commerce

$13.85

-0.14 (-1.00%)

18:24
07/27/17
07/27
18:24
07/27/17
18:24
Earnings
Heritage Commerce reports Q2 EPS 19c, consensus 19c »

Reports Q2 NII $24.9M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.